Back

Mavacamten induces a clinical, hemodynamic, and biomarker response beyond the primary endpoint in EXPLORER-HCM: results from a post hoc machine learning analysis

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Hypertrophic cardiomyopathy: not so rare, but not so easy Hypertrophic Cardiomyopathy Open Access ESC Congress 2022

About the speaker

Photo
Professor Iacopo Olivotto

University of Florence, Florence (Italy)

4 More presentations in this session

Presentation thumbnail
Metoprolol improves left ventricular longitudinal function at rest and during exercise in obstructive hypertrophic cardiomyopathy
Mrs A. Dybro (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
Prevalence and clinical correlates of clinical red flags for rare diseases in consecutive patients presenting with HCM phenotype
Doctor N. Maurizi (Lausanne, CH)
Abstract Slides Video
Presentation thumbnail
Temporal trends, characteristics and comorbidities of patients with hypertrophic cardiomyopathy in denmark from 2005-2018: A nationwide cohort study.
Doctor C. Zoerner (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Representativeness of EXPLORER-HCM trial and prevalence of eligibility criteria for Mavacamten in a nationwide cohort
Doctor M. Brandao (Madrid, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Hypertrophic cardiomyopathy: not so rare, but not so easy

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Echocardiographic changes in nonobstructive hypertrophic cardiomyopathy patients treated with mavacamten: A sub-study of the ODYSSEY-HCM trial
thumbnail
Congress Presentation
Hemodynamic and symptomatic response in real-world patients with hypertrophic obstructive cardiomyopathy and myosin inhibitor therapy
thumbnail
Congress Presentation
Mavacamten treatment in obstructive hypertrophic cardiomyopathy for up to 30 weeks: An integrated analysis of cardiac magnetic resonance data from a diverse population in randomized clinical trials

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources